Article Text

Download PDFPDF

CT-06 Missing outcomes in SLE clinical trials: impact on estimating treatment effects
  1. Mimi Kim1,
  2. Joan T Merrill2,
  3. Kenneth C Kalunian3,
  4. Leslie Hanrahan4 and
  5. Peter M Izmirly5
  1. 1Albert Einstein College of Medicine
  2. 2Oklahoma Medical Research Foundation
  3. 3University of California at San Diego
  4. 4Lupus Foundation of America
  5. 5New York University School of Medicine, USA


Background Missing data due to drop-out and loss to follow-up is a common problem in SLE trials. The usual approaches for handling this issue include analyzing only subjects with complete data (complete case analysis; CC), last observation carried forward (LOCF), or imputing non-responses for missing outcomes (non-responder imputation; NRI). However, the validity of these methods depends on strong assumptions about the missing data mechanism. Multiple imputation (MI) is a flexible model-based technique that accounts for uncertainty in the imputation process by generating several possible values for the missing data, resulting in multiple complete data sets. These are analyzed separately and results are combined. MI is being used more widely in different disease settings but has not been applied to analyze the primary outcome in a SLE trial. We explored the use of MI to address missing data in the composite outcome, SLE Responder Index (SRI)−5, using data from patients assigned to standard of care (SoC) in a 52 week trial.

Methods Data on 279 SLE patients randomized to SoC for 52 weeks who were receiving mycophenolate mofetil (MMF), azathioprine, or methotrexate at entry were obtained from the Lupus Foundation of America-Collective Data Analysis Initiative database. Multiple imputation using chained equations was applied to handle missing data in an analysis to evaluate differences in SRI-5 response rates at 52 weeks between patients on MMF and the other immunosuppressants (non-MMF). Three different imputation models were considered that included various combinations of longitudinal measures of disease activity (both composite and individual measures) and patient characteristics. Results were compared to estimates using the CC, LOCF, and NRI.

Results Missing data rates were 32% in the MMF and 23% in the non-MMF groups. As expected, the NRI missing data approach yielded the lowest response rates; the smallest and least significant estimates of between group differences were observed with LOCF (table 1). Group differences were magnified with all three MI models compared to results of other methods. Imputing SRI-5 directly (MI-1) versus the individual components (MI-2) yielded nearly identical results.

Conclusions Given the limitations of conventional approaches for handling missing data, the MI method should also be considered in SLE trials. However, results can vary depending on the imputation model that is used, and the assumptions required for validity of this and other missing data methods must be justified. Sensitivity analysis using different approaches is important to demonstrate robustness of results especially when missing data rates are non-negligible.

Abstract CT-06 Table 1

SRI-5 response rates at 52 weeks on SoC by immunosuppressant use

Acknowledgements Lupus Foundation of America Collective Data Analysis Initiative Group.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.